 Fluorodeoxyglucose F18
"Fluorodeoxyglucose F18" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
The compound is given by intravenous injection to do POSITRON-EMISSION TOMOGRAPHY for the assessment of cerebral and myocardial glucose metabolism in various physiological or pathological states including stroke and myocardial ischemia. It is also employed for the detection of malignant tumors including those of the brain, liver, and thyroid gland. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1162)
| Descriptor ID |
D019788
|
| MeSH Number(s) |
D09.254.229.500
|
| Concept/Terms |
Fluorodeoxyglucose F18- Fluorodeoxyglucose F18
- F18, Fluorodeoxyglucose
- 18F-FDG
- Fluorodeoxyglucose F 18
- F 18, Fluorodeoxyglucose
- Fludeoxyglucose F 18
- F 18, Fludeoxyglucose
- Fluorine-18-fluorodeoxyglucose
- Fluorine 18 fluorodeoxyglucose
- 18F Fluorodeoxyglucose
- Fluorodeoxyglucose, 18F
- 18FDG
|
Below are MeSH descriptors whose meaning is more general than "Fluorodeoxyglucose F18".
Below are MeSH descriptors whose meaning is more specific than "Fluorodeoxyglucose F18".
This graph shows the total number of publications written about "Fluorodeoxyglucose F18" by people in this website by year, and whether "Fluorodeoxyglucose F18" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1997 | 0 | 1 | 1 | | 1998 | 0 | 1 | 1 | | 1999 | 0 | 1 | 1 | | 2000 | 1 | 1 | 2 | | 2001 | 1 | 1 | 2 | | 2002 | 2 | 4 | 6 | | 2003 | 2 | 4 | 6 | | 2004 | 3 | 1 | 4 | | 2005 | 0 | 2 | 2 | | 2006 | 2 | 0 | 2 | | 2008 | 2 | 3 | 5 | | 2009 | 4 | 2 | 6 | | 2010 | 0 | 3 | 3 | | 2012 | 1 | 3 | 4 | | 2013 | 3 | 5 | 8 | | 2014 | 4 | 3 | 7 | | 2015 | 3 | 6 | 9 | | 2016 | 3 | 7 | 10 | | 2017 | 1 | 2 | 3 | | 2018 | 4 | 2 | 6 | | 2019 | 3 | 6 | 9 | | 2020 | 2 | 3 | 5 | | 2021 | 4 | 3 | 7 | | 2022 | 1 | 7 | 8 | | 2023 | 1 | 6 | 7 | | 2024 | 2 | 4 | 6 | | 2025 | 2 | 0 | 2 | | 2026 | 1 | 5 | 6 |
To return to the timeline, click here.
Below are the most recent publications written about "Fluorodeoxyglucose F18" by people in Profiles.
-
Johnson J, Griffin L, Vickery K, Randall E. Spleens With Disseminated Lymphoma Exhibit Higher Standardized Uptake Value Maximum, Metabolic Tumor Volumes, and Total Lesion Glycolysis on Fluorine-18 Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography. Vet Radiol Ultrasound. 2026 Nov; 67(6):e70241.
-
Maisenbacher M, Alshaqi O, Peng X, Schmidt C, Uberti M, Phatak V, Taraschenko O. Cognitive-metabolic relationship in temporal lobe epilepsy: A systematic review. Epilepsy Behav. 2026 11; 184:111224.
-
Valic MS, Najjar E, Zheng M, Townson JL, Chan HHL, Tzelnick S, Ruaro A, El-Sayes A, Halim M, Schimmer P, Zhang CJ, Ye T, Jiang W, Chen J, Irish JC, Zheng G. Porphyrin-lipid nanotheranostics for multimodal imaging of nodal disease in preclinical oral cancers. Theranostics. 2026; 16(13):7108-7123.
-
Middlebrooks EH, Lin C, Pooley RA, Spangler-Bickell MG, Smith A, Litwiller D, Patel V, Cai Y, Gupta V, Soni N. Feasibility of MR-Guided PET Reconstruction in Detection of Focal Cortical Dysplasia. AJNR Am J Neuroradiol. 2026 04 02; 47(4):1061-1064.
-
Boydston JA, Yang HJ, Mazur S, Bohannon JK, Lackemeyer MG, Byrum R, Bartos C, Cooper K, Reeder R, Kendall W, Conway K, Partner K, Vaughan N, Calcagno C, Godwin G, Cong Y, Crozier I, Kuhn JH, Dabisch PA, Mani V. PET/CT imaging-based quantification of respiratory tract deposition of small- and large-particle aerosols versus intranasal bolus in rodents. Inhal Toxicol. 2026 May; 38(5):225-236.
-
Gowdy SC, Flerlage JE, Seelisch J, Palese M, Bradshaw T, Castellino SM, Cho S, Dieckmann K, Hoppe BS, Howard S, Kelly KM, Kurch L, Lai HA, Lopci E, Lucas JT, Mauz-Körholz C, McCarten KM, Pandit-Taskar N, Schöder H, Steglich J, Stoevesandt D, Voss SD, Milgrom SA. Prognostic role of PET/CT volumetric parameters in paediatric Hodgkin lymphoma: A systematic review and expert recommendations from the International SEARCH for CAYAHL Group. Br J Haematol. 2026 Apr; 208(4):1185-1195.
-
Donnelly R, Franciosi AN, Forde SH, McDermott M, Keane MP, Murphy DJ, McGrath EE, McCarthy C. Deciphering the Role of Fluorodeoxyglucose-Positron Emission Tomography/CT Imaging in the Management of Sarcoidosis. Chest. 2025 07; 168(1):146-155.
-
Zugasti I, Tormo-Ratera M, Oliver-Caldés A, Soler-Perromat JC, González-Calle V, Moreno DF, Cabañas V, López-Muñoz N, Bartolomé-Solanas Á, Español-Rego M, Reguera-Ortega JL, Rosiñol L, López-Corral L, Tovar N, Rodríguez-Lobato LG, Alvarez Perez RM, Varea S, Olesti E, Gomez-Grande A, Frutos L, Tamayo P, Juan M, Moraleda JM, Urbano-Ispizua Á, González-Navarro EA, Martínez-López J, Mateos MV, Tomás X, Setoain X, Fernández de Larrea C. Clinical impact of [18F]FDG-PET/CT in ARI0002h treatment, a CAR-T against BCMA for relapsed/refractory multiple myeloma. Blood Adv. 2025 Feb 11; 9(3):571-582.
-
O'Donnell C, Ryan O, Hogan AE, Killick D, Crilly S, Dodd JD, Murphy DJ, Ryan S, O'Shea D. GLP-1 therapy increases visceral adipose tissue metabolic activity: lessons from a randomized controlled trial in obstructive sleep apnea. Obesity (Silver Spring). 2024 Nov; 32(11):2077-2081.
-
Edwards DM, Schonewolf CA, Rice JD, Schipper M, Haken RKT, Matuszak M, Balter J, Jarema D, Arenberg DA, Piert M, Qin A, Kalemkerian GP, Schneider BJ, Ramnath N, Chapman CH, Elliott DA, Lawrence TS, Hearn J, Hayman JA, Jolly S. Phase 2 Trial Assessing Toxicity of Personalized Response-Based Radiation Treatment in Patients With Locally Advanced Non-Small Cell Lung Cancer. Int J Radiat Oncol Biol Phys. 2024 Dec 01; 120(5):1332-1343.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|